Atlas Trials

A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

Clinical trial NCT03294083 · COMPLETED

Trial details

NCT number
NCT03294083
Sponsor
SillaJen, Inc.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Renal Cell Carcinoma
Start date
2018-06-19
Primary completion
2023-02-16
Enrollment
95

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.